Rebiotix Inc. Report issue

For profit Phase 2 Phase 3
Founded: Rockville MN United States (2011)
Status: Acquired by Ferring (2018)

Organization Overview

First Clinical Trial
2013
NCT01925417
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2019

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Rebiotix Inc.

Active Ingredients

Drugs in Phase 3 Trials (1)

allogeneic microbiota (5 trials)

Drugs in Phase 2 Trials (2)

human fecal microbiota (Reybota) (2 trials)

rbx7455 (3 trials)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Brain Diseases (Phase 2)

Breast Neoplasms (Phase 1)

Clostridium Infections (Phase 3)

Communicable Diseases (Phase 3)

Diarrhea (Phase 2)

Enterocolitis (Phase 2)

Hepatic Encephalopathy (Phase 2)

Infections (Phase 3)

Liver Cirrhosis (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 10
  • # of Trial APIs: 3